# Avelumab combinations in advanced TNBC

Source: https://onco.cc/trials/nct03971409/  
OnCo record `nct03971409` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

This study tests avelumab with different drug combinations in advanced triple-negative breast cancer. Some groups receive treatment intended to stimulate the immune system before the main combination.

## Summary

This study tests avelumab with different drug combinations in advanced triple-negative breast cancer. Some groups receive treatment intended to stimulate the immune system before the main combination.

Interventional study registered as NCT03971409, sponsored by Laura Huppert, MD, BA. Registry phase: 2. Registry enrollment is 145 participants (actual). Registry status checked October 10, 2026: active not recruiting. UCSF lists this study as closed to local enrollment; local availability and overall registry status are separate. See the registry for full eligibility and current sites.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-10-10
- Also known as: Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer
- Tags: ucsf-breast-coverage; interventional
- Registry id: NCT03971409
- Phase: 2
- Setting: Stage IV or unresectable recurrent triple-negative breast cancer
- Sponsor: Laura Huppert, MD, BA
- Enrolled: 145

## Sources

- ClinicalTrials.gov NCT03971409: https://clinicaltrials.gov/study/NCT03971409
- UCSF study listing and local availability: https://clinicaltrials.ucsf.edu/trial/NCT03971409

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- drugs: [Avelumab](https://onco.cc/drugs/avelumab/), [Binimetinib](https://onco.cc/drugs/binimetinib/), [Sacituzumab govitecan](https://onco.cc/drugs/sacituzumab-govitecan/), [Utomilumab](https://onco.cc/drugs/utomilumab/)
- institutions: [UCSF Helen Diller Family Comprehensive Cancer Center](https://onco.cc/institutions/ucsf/)

---
JSON: https://onco.cc/api/v1/entities/nct03971409.json